Binding of S100 proteins to RAGE: An update

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 6, 2009, Pages 993-1007

  Leclerc, Estelle ^a   Fritz, Günter ^b   Vetter, Stefan W ^a   Heizmann, Claus W ^c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

RAGE; S100; Surface plasmon resonance

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM BINDING PROTEIN; CALCYCLIN; CALGRANULIN A; IMMUNOGLOBULIN; PROTEIN S 100; PROTEIN S100A1; PROTEIN S100A11; PROTEIN S100A12; PROTEIN S100A13; PROTEIN S100A2; PROTEIN S100A5; PROTEIN S100B; PROTEIN S100P; PSORIASIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL ASSAY; HUMAN; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

ANIMALS; HUMANS; LIGANDS; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 67349265963     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.11.016     Document Type: Review

References (357)

1. Heizmann C.W., Fritz G., and Schäfer B.W. S100 proteins: structure, functions and pathology. Front Biosci. 7 (2002) d1356-68
2. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60 (2003) 540-551
3. 2+-binding protein family. Biometals 11 (1998) 383-397
4. E. Leclerc, E. Stürchler and C.W. Heizmann. in (Mikoshiba, ed.) Handbook of Neurochemistry and Molecular Neurobiology, Springer, New York in press.
5. Marenholz I., Lovering R.C., and Heizmann C.W. An update of the S100 nomenclature. Biochim. Biophys. Acta 1763 (2006) 1282-1283
6. Heizmann C.W., Ackermann G.E., and Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell. Biochem. 45 (2007) 93-138
7. Schaub M.C., and Heizmann C.W. Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem. Biophys. Res. Commun. 369 (2008) 247-264
8. Zimmer D.B., Wright Sadosky P., and Weber D.J. Molecular mechanisms of S100-target protein interactions. Microsc. Res. Tech. 60 (2003) 552-559
9. Fritz G., and Heizmann C.W. In: Messerschmidt A., Bode W., and Cygler M. (Eds). Handbook of Metalloproteins Vol. 3 (2004), Wiley, Chichester 529-540
10. Krebs J., and Heizmann C.W. In: Krebs J., and Michalak M. (Eds). Calcium: A Matter of Life Or Death (2007), Elsevier, Amsterdam 51-93
11. Santamaria-Kisiel L., Rintala-Dempsey A.C., and Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem. J. 396 (2006) 201-214
12. 2+-binding helix-loop-helix EF-hand motifs. Biochem. J. 405 (2007) 199-201
13. Koch M., Bhattacharya S., Kehl T., Gimona M., Vasak M., Chazin W., Heizmann C.W., Kroneck P.M., and Fritz G. Implications on zinc binding to S100A2. Biochim. Biophys. Acta 1773 (2007) 457-470
14. 2+-binding proteins. Nat. Struct. Biol. 1 (1994) 239-245
15. Wang G., Zhang S., Fernig D.G., Spiller D., Martin-Fernandez M., Zhang H., Ding Y., Rao Z., Rudland P.S., and Barraclough R. Heterodimeric interaction and interfaces of S100A1 and S100P. Biochem. J. 382 (2004) 375-383
16. Rustandi R.R., Baldisseri D.M., Inman K.G., Nizner P., Hamilton S.M., Landar A., Zimmer D.B., and Weber D.J. Three-dimensional solution structure of the calcium-signaling protein apo-S100A1 as determined by NMR. Biochemistry 41 (2002) 788-796
17. Tarabykina S. Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast two-hybrid system. FEBS Lett. 475 (2000) 187-191
18. Lugering N., Stoll R., Schmid K.W., Kucharzik T., Stein H., Burmeister G., Sorg C., and Domschke W. The myeloic related protein MRO8/14 (27E10 antigen)-usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Eur. J. Clin. Invest. 25 (1995) 659-664
19. Ostendorp T., Leclerc E., Galichet A., Koch M., Demling N., Weigle B., Heizmann C.W., Kroneck P.M., and Fritz G. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 26 (2007) 3868-3878
20. 2+ signaling in neurons induced by the S100A4 protein. Mol. Cell. Biol. 26 (2006) 3625-3638
21. Leukert N., Vogl T., Strupat K., Reichelt R., Sorg C., and Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J. Mol. Biol. 359 (2006) 961-972
22. Moroz O.V., Antson A.A., Dodson E.J., Burrell H.J., Grist S.J., Lloyd R.M., Maitland N.J., Dodson G.G., Wilson K.S., Lukanidin E., and Bronstein I.B. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr. D. Biol. Crystallogr. 58 (2002) 407-413
23. Moroz O.V., Dodson G.G., Wilson K.S., Lukanidin E., and Bronstein I.B. Multiple structural states of S100A12: a key to its functional diversity. Microsc. Res. Tech. 60 (2003) 581-592
24. Xie J., Burz D.S., He W., Bronstein I.B., Lednev I., and Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem. 282 (2007) 4218-4231
25. Gerlach R., Demel G., Konig H.G., Gross U., Prehn J.H., Raabe A., Seifert V., and Kogel D. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 141 (2006) 1697-1701
26. Tramontina F., Tramontina A.C., Souza D.F., Leite M.C., Gottfried C., Souza D.O., Wofchuk S.T., and Goncalves C.A. Glutamate uptake is stimulated by extracellular S100B in hippocampal astrocytes. Cell. Mol. Neurobiol. 26 (2006) 81-86
27. Ellis E.F., Willoughby K.A., Sparks S.A., and Chen T. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. J. Neurochem. 101 (2007) 1463-1470
28. 2+ levels regulate the alternative cell density-dependent secretion of S100B in human glioblastoma cells. J. Biol. Chem. 276 (2001) 30819-30826
29. Perrone L., Peluso G., and Melone M.A. RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. J. Cell. Physiol. 217 (2008) 60-71
30. Torabian S., and Kashani-Sabet M. Biomarkers for melanoma. Curr. Opin. Oncol. 17 (2005) 167-171
31. Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., and Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem. 272 (1997) 9496-9502
32. Boussac M., and Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 21 (2000) 665-672
33. Stary M., Schneider M., Sheikh S.P., and Weitzer G. Parietal endoderm secreted S100A4 promotes early cardiomyogenesis in embryoid bodies. Biochem. Biophys. Res. Commun. 343 (2006) 555-563
34. Kiewitz R., Acklin C., Minder E., Huber P.R., Schäfer B.W., and Heizmann C.W. S100A1, a new marker for acute myocardial ischemia. Biochem. Biophys. Res. Commun. 274 (2000) 865-871
35. Komada T., Araki R., Nakatani K., Yada I., Naka M., and Tanaka T. Novel specific chemtactic receptor for S100L protein on guinea pig eosinophils. Biochem. Biophys. Res. Commun. 220 (1996) 871-874
36. Leclerc E., Fritz G., Weibel M., Heizmann C.W., and Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 282 (2007) 31317-31331
37. Jinquan T., Vorum H., Larsen C.G., Madsen P., Rasmussen H.H., Gesser B., Etzerodt M., Honore B., Celis J.E., and Thestrup-Pedersen K. Psoriasin: a novel chemotactic protein. J. Invest. Dermatol. 107 (1996) 5-10
38. Glaser R., Harder J., Lange H., Bartels J., Christophers E., and Schroder J.M. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat. Immunol. 6 (2005) 57-64
39. Li X., de Leeuw E., and Lu W. Total chemical synthesis of human psoriasin by native chemical ligation. Biochemistry 44 (2005) 14688-14694
40. Lee K.C., and Eckert R.L. S100A7 (Psoriasin)-mechanism of antibacterial action in wounds. J. Invest. Dermatol. 127 (2007) 945-957
41. Schmidt A.M., Hofmann M., Taguchi A., Yan S.D., and Stern D.M. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin. Thromb. Hemost. 26 (2000) 485-493
42. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 7 (2007) 711-724
43. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267 (1992) 14987-14997
44. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., and Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992) 14998-15004
45. Kiselyov V.V., Berezin V., Maar T.E., Soroka V., Edvardsen K., Schousboe A., and Bock E. The First Immunoglobulin-like Neural Cell Adhesion Molecule (NCAM) Domain is involved in double-reciprocal Interaction with the Second Immunoglobulin-like NCAM Domain and in Heparin Binding. J. Biol. Chem. 272 (1997) 10125-10134
46. Barclay A.N. Membrane proteins with immunoglobulin-like domains-a master superfamily of interaction molecules. Semin. Immunol. 15 (2003) 215-223
47. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Grone H.J., Kurschus F.C., Schmidt A.M., Yan S.D., Martin E., Schleicher E., Stern D.M., Hammerling G.G., Nawroth P.P., and Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
48. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498 (2000) 99-111
49. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., and Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 283 (2008) 27255-27269
50. Srikrishna G., Huttunen H.J., Johansson L., Weigle B., Yamaguchi Y., Rauvala H., and Freeze H.H. N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem. 80 (2002) 998-1008
51. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., Nowygrod R., Neeper M., Przysiecki C., Shaw A., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143 (1993) 1699-1712
52. Giron M.D., Vargas A.M., Suarez M.D., and Salto R. Sequencing of two alternatively spliced mRNAs corresponding to the extracellular domain of the rat receptor for advanced glycosylation end products (RAGE). Biochem. Biophys. Res. Commun. 251 (1998) 230-234
53. Schlueter C., Hauke S., Flohr A.M., Rogalla P., and Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms-a result of regulated alternative splicing?. Biochim. Biophys. Acta 1630 (2003) 1-6
54. Malherbe P., Richards J.G., Gaillard H., Thompson A., Diener C., Schuler A., and Huber G. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res. Mol. Brain Res. 71 (1999) 159-170
55. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., Grant P.J., and Schmidt A.M. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22 (2008) 1572-1580
56. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., and Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
57. Park I.H., Yeon S.I., Youn J.H., Choi J.E., Sasaki N., Choi I.H., and Shin J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 40 (2004) 1203-1211
58. Ding Q., and Keller J.N. Evaluation of RAGE isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 1746 (2005) 18-27
59. Ding Q., and Keller J.N. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett. 373 (2005) 67-72
60. Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., Inoko H., and Ikemura T. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23 (1994) 408-419
61. Galichet A., Weibel M., and Heizmann C.W. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem. Biophys. Res. Commun. 370 (2008) 1-5
62. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., Saftig P., and Bianchi M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22 10 (2008) 3716-3727
63. Mukherjee T.K., Mukhopadhyay S., and Hoidal J.R. Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir. Physiol. Neurobiol. 162 3 (2008) 210-215
64. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., and Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
65. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
66. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907-913
67. Wilton R., Yousef M.A., Saxena P., Szpunar M., and Stevens F.J. Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expression Purif. 47 (2006) 25-35
68. Sousa M.M., Yan S.D., Stern D., and Saraiva M.J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. 80 (2000) 1101-1110
69. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., and Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
70. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K.T., and Nawroth P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198 (2003) 1507-1515
71. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
72. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., and Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96 (1995) 1395-1403
73. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., and Lan H.Y. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 164 (2004) 1389-1397
74. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., and De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
75. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95 (2004) 233-238
76. Ramasamy R., Yan S.F., and Schmidt A.M. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol. Nutr. Food Res. 51 (2007) 1111-1115
77. Schleicher E.D., Wagner E., and Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99 (1997) 457-468
78. Ikeda K., Higashi T., Sano H., Jinnouchi Y., Yoshida M., Araki T., Ueda S., and Horiuchi S. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35 (1996) 8075-8083
79. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., and Baynes J.W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34 (1995) 10872-10878
80. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., and Schmidt A.M. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274 (1999) 31740-31749
81. Boulanger E., Grossin N., Wautier M.P., Taamma R., and Wautier J.L. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int. 71 (2007) 126-133
82. Somoza V., Lindenmeier M., Hofmann T., Frank O., Erbersdobler H.F., Baynes J.W., Thorpe S.R., Heidland A., Zill H., Bek S., Huber J., Weigle T., Scheidler S., Busch A.E., and Sebekova K. Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats. Ann. N. Y. Acad. Sci. 1043 (2005) 492-500
83. Valencia J.V., Mone M., Koehne C., Rediske J., and Hughes T.E. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products (AGEs). Diabetologia 47 (2004) 844-852
84. Buetler T.M., Leclerc E., Baumeyer A., Latado H., Newell J., Adolfsson O., Parisod V., Richoz J., Maurer S., Foata F., Piguet D., Junod S., Heizmann C.W., and Delatour T. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol. Nutr. Food Res. 52 (2008) 370-378
85. Uetz-von Allmen E., Koch M., Fritz G., and Legler D. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68 (2008) 748-758
86. Yamamoto Y., Yonekura H., Watanabe T., Sakurai S., Li H., Harashima A., Myint K.M., Osawa M., Takeuchi A., Takeuchi M., and Yamamoto H. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res. Clin. Pract. 77 Suppl. 1 (2007) S30-40
87. Osawa M., Yamamoto Y., Munesue S., Murakami N., Sakurai S., Watanabe T., Yonekura H., Uchigata Y., Iwamoto Y., and Yamamoto H. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim. Biophys. Acta 1770 (2007) 1468-1474
88. Bianchi M.E., Beltrame M., and Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243 (1989) 1056-1059
89. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev., Immunol. 5 (2005) 331-342
90. Stros M., Ozaki T., Bacikova A., Kageyama H., and Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 277 (2002) 7157-7164
91. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
92. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
93. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22 (2003) 5551-5560
94. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H., and Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192 (2000) 565-570
95. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., and Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166 (2005) 1259-1263
96. van Beijnum J.R., Buurman W.A., and Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11 (2008) 91-99
97. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255 (2004) 351-366
98. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
99. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
100. Du Yan S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., and Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5296-5301
101. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M., and Du Yan S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23 (2004) 4096-4105
102. Stürchler E., Galichet A., Weibel M., Leclerc E., and Heizmann C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 28 (2008) 5149-5158
103. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., and Roher A.E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 1741 (2005) 199-205
104. Moore B.W. A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun. 19 (1965) 739-744
105. Van Eldik L.J., and Zimmer D.B. Secretion of S-100 from rat C6 glioma cells. Brain Res. 436 (1987) 367-370
106. Pinto S.S., Gottfried C., Mendez A., Goncalves D., Karl J., Goncalves C.A., Wofchuk S., and Rodnight R. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett. 486 (2000) 203-207
107. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., and Keilhoff G. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 154 (2008) 496-503
108. Baudier J., Glasser N., and Gerard D. Ions binding to S100 proteins. I. Calcium- and zinc-binding properties of bovine brain S100 alpha alpha, S100a (alpha beta), and S100b (beta beta) protein: Zn2+ regulates Ca2+ binding on S100b protein. J. Biol. Chem. 261 (1986) 8192-8203
109. Nishikawa T., Lee I.S., Shiraishi N., Ishikawa T., Ohta Y., and Nishikimi M. Identification of S100b protein as copper-binding protein and its suppression of copper-induced cell damage. J. Biol. Chem. 272 (1997) 23037-23041
110. Drohat A.C., Amburgey J.C., Abildgaard F., Starich M.R., Baldisseri D., and Weber D.J. Solution structure of rat apo-S100B(beta beta) as determined by NMR spectroscopy. Biochemistry 35 (1996) 11577-11588
111. Kilby P.M., Van Eldik L.J., and Roberts G.C. The solution structure of the bovine S100B protein dimer in the calcium-free state. Structure 4 (1996) 1041-1052
112. Drohat A.C., Baldisseri D.M., Rustandi R.R., and Weber D.J. Solution structure of calcium-bound rat S100B(betabeta) as determined by nuclear magnetic resonance spectroscopy. Biochemistry 37 (1998) 2729-2740
113. Matsumura H., Shiba T., Inoue T., Harada S., and Kai Y. A novel mode of target recognition suggested by the 2.0 Å structure of holo S100B from bovine brain. Structure 6 (1998) 233-241
114. Smith S.P., and Shaw G.S. A novel calcium-sensitive switch revealed by the structure of human S100B in the calcium-bound form. Structure 6 (1998) 211-222
115. Rustandi R.R., Baldisseri D.M., and Weber D.J. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 7 (2000) 570-574
116. Bhattacharya S., Large E., Heizmann C.W., Hemmings B., and Chazin W.J. Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. Biochemistry 42 (2003) 14416-14426
117. Inman K.G., Yang R., Rustandi R.R., Miller K.E., Baldisseri D.M., and Weber D.J. Solution NMR structure of S100B bound to the high-affinity target peptide TRTK-12. J. Mol. Biol. 324 (2002) 1003-1014
118. Rothermundt M., Peters M., Prehn J.H., and Arolt V. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 60 (2003) 614-632
119. Hauschild A., Engel G., Brenner W., Glaser R., Monig H., Henze E., and Christophers E. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56 (1999) 338-344
120. Bell K., Shokrian D., Potenzieri C., and Whitaker-Azmitia P.M. Harm avoidance, anxiety, and response to novelty in the adolescent S-100beta transgenic mouse: role of serotonin and relevance to Down syndrome. Neuropsychopharmacology 28 (2003) 1810-1816
121. Nishiyama H., Takemura M., Takeda T., and Itohara S. Normal development of serotonergic neurons in mice lacking S100B. Neurosci. Lett. 321 (2002) 49-52
122. Dyck R.H., Bogoch I.I., Marks A., Melvin N.R., and Teskey G.C. Enhanced epileptogenesis in S100B knockout mice. Brain Res. Mol. Brain Res. 106 (2002) 22-29
123. Xiong Z., O'Hanlon D., Becker L.E., Roder J., MacDonald J.F., and Marks A. Enhanced calcium transients in glial cells in neonatal cerebellar cultures derived from S100B null mice. Exp. Cell Res. 257 (2000) 281-289
124. Gerlai R., and Roder J. Abnormal exploratory behavior in transgenic mice carrying multiple copies of the human gene for S100 beta. J. Psychiatry. Neurosci. 20 (1995) 105-112
125. Gerlai R., and Roder J. Spatial and nonspatial learning in mice: effects of S100 beta overexpression and age. Neurobiol. Learn. Mem. 66 (1996) 143-154
126. Winocur G., Roder J., and Lobaugh N. Learning and memory in S100-beta transgenic mice: an analysis of impaired and preserved function. Neurobiol. Learn. Mem. 75 (2001) 230-243
127. Huttunen H.J., Kuja-Panula J., Sorci G., Agneletti A.L., Donato R., and Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 275 (2000) 40096-40105
128. Kögel D., Peters M., König H.G., Hashémi S.M.A., Bui N.T., Arolt V., Rothermundt M., and Prehn J.H.M. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience 127 (2004) 913-920
129. Businaro R., Leone S., Fabrizi C., Sorci G., Donato R., Lauro G.M., and Fumagalli L. S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. J. Neurosci. Res. 83 (2006) 897-906
130. Schmidt A., Kuhla B., Bigl K., Munch G., and Arendt T. Cell cycle related signaling in Neuro2a cells proceeds via the receptor for advanced glycation end products. J. Neural Transm. 114 (2007) 1413-1424
131. Vincent A.M., Perrone L., Sullivan K.A., Backus C., Sastry A.M., Lastoskie C., and Feldman E.L. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148 (2007) 548-558
132. Ponath G., Schettler C., Kaestner F., Voigt B., Wentker D., Arolt V., and Rothermundt M. Autocrine S100B effects on astrocytes are mediated via RAGE. J. Neuroimmunol. 184 (2007) 214-222
133. Adami C., Bianchi R., Pula G., and Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim. Biophys. Acta 1742 (2004) 169-177
134. Bianchi R., Adami C., Giambanco I., and Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J. Leukocyte Biol. 81 (2007) 108-118
135. Bianchi R., Giambanco I., and Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging (2008) [Electronic publication ahead of print]
136. Shanmugam N., Kim Y.S., Lanting L., and Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 278 (2003) 34834-34844
137. 2- generation by mononuclear phagocytes in diabetes. J. Leukocyte Biol. 81 (2007) 520-527
138. Shanmugam N., Ransohoff R.M., and Natarajan R. Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100B. J. Biol. Chem. 281 (2006) 31212-31221
139. Feng L., Matsumoto C., Schwartz A., Schmidt A.M., Stern D.M., and Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 28 (2005) 379-384
140. Shaw S.S., Schmidt A.M., Banes A.K., Wang X., Stern D.M., and Marrero M.B. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 52 (2003) 2381-2388
141. Reddy M.A., Li S.L., Sahar S., Kim Y.S., Xu Z.G., Lanting L., and Natarajan R. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem. 281 (2006) 13685-13693
142. Sorci G., Riuzzi F., Agneletti A.L., Marchetti C., and Donato R. S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner. Mol. Cell. Biol. 23 (2003) 4870-4881
143. Sorci G., Riuzzi F., Agneletti A.L., Marchetti C., and Donato R. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J. Cell. Physiol. 199 (2004) 274-283
144. Dattilo B.M., Fritz G., Leclerc E., Kooi C.W., Heizmann C.W., and Chazin W.J. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46 (2007) 6957-6970
145. Raghavan M., Wang Y., and Bjorkman P.J. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11200-11204
146. Zimmer D.B., Chaplin J., Baldwin A., and Rast M. S100-mediated signal transduction in the nervous system and neurological diseases. Cell. Mol. Biol. 51 (2005) 201-214
147. Most P., Bernotat J., Ehlermann P., Pleger S.T., Reppel M., Borries M., Niroomand F., Pieske B., Janssen P.M., Eschenhagen T., Karczewski P., Smith G.L., Koch W.J., Katus H.A., and Remppis A. S100A1: a regulator of myocardial contractility. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13889-13894
148. Remppis A., Pleger S.T., Most P., Lindenkamp J., Ehlermann P., Schweda C., Loffler E., Weichenhan D., Zimmermann W., Eschenhagen T., Koch W.J., and Katus H.A. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J. Gene. Med. 6 (2004) 387-394
149. Most P., Pleger S.T., Volkers M., Heidt B., Boerries M., Weichenhan D., Loffler E., Janssen P.M., Eckhart A.D., Martini J., Williams M.L., Katus H.A., Remppis A., and Koch W.J. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J. Clin. Invest. 114 (2004) 1550-1563
150. Du X.J., Cole T.J., Tenis N., Gao X.M., Kontgen F., Kemp B.E., and Heierhorst J. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol. Cell. Biol. 22 (2002) 2821-2829
151. Most P., Remppis A., Pleger S.T., Katus H.A., and Koch W.J. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R568-577
152. Ackermann G.E., Domenighetti A.A., Deten A., Bonath I., Marenholz I., Pedrazzini T., Erne P., and Heizmann C.W. S100A1 deficiency results in prolonged ventricular repolarization in response to sympathetic activation. Gen. Physiol. Biophys. 27 (2008) 127-142
153. Ackermann G.E., Marenholz I., Wolfer D.P., Chan W.Y., Schäfer B., Erne P., and Heizmann C.W. S100A1-deficient male mice exhibit increased exploratory activity and reduced anxiety-related responses. Biochim. Biophys. Acta 1763 (2006) 1307-1319
154. Lee S.W., Tomasetto C., and Sager R. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2825-2829
155. Mandinova A., Atar D., Schafer B.W., Spiess M., Aebi U., and Heizmann C.W. Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. J. Cell. Sci. 111 Pt. 14 (1998) 2043-2054
156. Glenney Jr. J.R., Kindy M.S., and Zokas L. Isolation of a new member of the S100 protein family: amino acid sequence, tissue, and subcellular distribution. J. Cell Biol. 108 (1989) 569-578
157. Zhang T., Woods T.L., and Elder J.T. Differential responses of S100A2 to oxidative stress and increased intracellular calcium in normal, immortalized, and malignant human keratinocytes. J. Invest. Dermatol. 119 (2002) 1196-1201
158. Koch M., Diez J., and Fritz G. Crystal structure of Ca2+ -free S100A2 at 1.6-A resolution. J. Mol. Biol. 378 (2008) 931-940
159. Maelandsmo G.M., Florenes V.A., Mellingsaeter T., Hovig E., Kerbel R.S., and Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int. J. Cancer 74 (1997) 464-469
160. Gupta S., Hussain T., MacLennan G.T., Fu P., Patel J., and Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J. Clin. Oncol. 21 (2003) 106-112
161. Suzuki F., Oridate N., Homma A., Nakamaru Y., Nagahashi T., Yagi K., Yamaguchi S., Furuta Y., and Fukuda S. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol. Rep. 14 (2005) 1493-1498
162. Feng G., Xu X., Youssef E.M., and Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res. 61 (2001) 7999-8004
163. Lee S.W., Tomasetto C., Swisshelm K., Keyomarsi K., and Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2504-2508
164. Imazawa M., Hibi K., Fujitake S., Kodera Y., Ito K., Akiyama S., and Nakao A. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res. 25 (2005) 1247-1250
165. Smith S.L., Gugger M., Hoban P., Ratschiller D., Watson S.G., Field J.K., Betticher D.C., and Heighway J. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br. J. Cancer 91 (2004) 1515-1524
166. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., Harper J., Yoshida C., Riggins G.J., Frierson Jr. H.F., and Powell S.M. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62 (2002) 6823-6826
167. Hough C.D., Cho K.R., Zonderman A.B., Schwartz D.R., and Morin P.J. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61 (2001) 3869-3876
168. Mueller A., Schäfer B.W., Ferrari S., Weibel M., Makek M., Hochli M., and Heizmann C.W. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J. Biol. Chem. 280 (2005) 29186-29193
169. Fernandez-Fernandez M.R., Rutherford T.J., and Fersht A.R. Members of the S100 family bind p53 in two distinct ways. Protein Sci. 17 (2008) 1663-1670
170. Matsubara D., Niki T., Ishikawa S., Goto A., Ohara E., Yokomizo T., Heizmann C.W., Aburatani H., Moriyama S., Moriyama H., Nishimura Y., Funata N., and Fukayama M. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 96 (2005) 844-857
171. Shimamoto S., Takata M., Tokuda M., Oohira F., Tokumitsu H., and Kobayashi R. Interactions of S100A2 and S100A6 with the tetratricopeptide repeat proteins, Hsp90/Hsp70-organizing protein and kinesin-light chain. J. Biol. Chem. 283 (2008) 28246-28258
172. 2+-binding protein family. Genes Dev. 3 (1989) 1086-1093
173. Grigorian M.S., Tulchinsky E.M., Zain S., Ebralidze A.K., Kramerov D.A., Kriajevska M.V., Georgiev G.P., and Lukanidin E.M. The mts-1 gene and control of tumor metastasis. Gene 135 (1993) 229-238
174. Helfman D.M., Kim E.J., Lukanidin E., and Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br. J. Cancer 92 (2005) 1955-1958
175. Garrett S.C., Varney K.M., Weber D.J., and Bresnick A.R. S100A4, a mediator of metastasis. J. Biol. Chem. 281 (2006) 677-680
176. Åberg F., and Kozlova E.N. Metastasis-associated mts1 (S100A4) protein in the developing and adult central nervous system. J. Comp. Neurol. 424 (2000) 269-282
177. Kozlova E.N., and Lukanidin E. Metastasis-associated mts1 (S100A4) protein is selectively expressed in white matter astrocytes and is up-regulated after peripheral nerve or dorsal root injury. Glia 27 (1999) 249-258
178. Kozlova E.N., and Lukanidin E. Mts1 protein expression in the central nervous system after injury. Glia 37 (2002) 337-348
179. Vallely K.M., Rustandi R.R., Ellis K.C., Varlamova O., Bresnick A.R., and Weber D.J. Solution structure of human Mts1 (S100A4) as determined by NMR spectroscopy. Biochemistry 41 (2002) 12670-12680
180. Pathuri P., Vogeley L., and Luecke H. Crystal structure of metastasis-associated protein S100A4 in the active calcium-bound form. J. Mol. Biol. 383 (2008) 62-77
181. Gingras A.R., Basran J., Prescott A., Kriajevska M., Bagshaw C.R., and Barsukov I.L. Crystal structure of the Ca(2+)-form and Ca(2+)-binding kinetics of metastasis-associated protein, S100A4. FEBS Lett. 582 (2008) 1651-1656
182. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., and Ambartsumian N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer. Res. 65 (2005) 3772-3780
183. N. Ambartsumian, M. Grigorian and E. Lukanidin, Genetically modified mouse models to study the role of metastasis-promoting S100A4(mts1) protein in metastatic mammary cancer, J Dairy Res 72 Spec No (2005) 27-33.
184. Kim E.J., and Helfman D.M. Characterization of the metastasis-associated protein, S100A4. Roles of calcium binding and dimerization in cellular localization and interaction with myosin. J. Biol. Chem. 278 (2003) 30063-30073
185. Takenaga K., Nakamura Y., Sakiyama S., Hasegawa Y., Sato K., and Endo H. Binding of pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin. J. Cell Biol. 124 (1994) 757-768
186. Ford H.L., Salim M.M., Chakravarty R., Aluiddin V., and Zain S.B. Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene 11 (1995) 2067-2075
187. Li Z.H., and Bresnick A.R. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res. 66 (2006) 5173-5180
188. Li Z.H., Spektor A., Varlamova O., and Bresnick A.R. Mts1 regulates the assembly of nonmuscle myosin-IIA. Biochemistry 42 (2003) 14258-14266
189. Mathisen B., Lindstad R.I., Hansen J., El-Gewely S.A., Maelandsmo G.M., Hovig E., Fodstad O., Loennechen T., and Winberg J.O. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin. Exp. Metastasis 20 (2003) 701-711
190. Bjornland K., Winberg J.O., Odegaard O.T., Hovig E., Loennechen T., Aasen A.O., Fodstad O., and Maelandsmo G.M. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 59 (1999) 4702-4708
191. Yammani R.R., Carlson C.S., Bresnick A.R., and Loeser R.F. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 54 (2006) 2901-2911
192. Schäfer B.W., Fritschy J.M., Murmann P., Troxler H., Durussel I., Heizmann C.W., and Cox J.A. Brain S100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand superfamily. J. Biol. Chem. 275 (2000) 30623-30630
193. Teratani T., Watanabe T., Yamahara K., Kumagai H., Ishikawa A., Arai K., and Nozawa R. Restricted expression of calcium-binding protein S100A5 in human kidney. Biochem. Biophys. Res. Commun. 291 (2002) 623-627
194. Chan W.Y., Xia C.L., Dong D.C., Heizmann C.W., and Yew D.T. Differential expression of S100 proteins in the developing human hippocampus and temporal cortex. Microsc. Res. Tech. 60 (2003) 600-613
195. Camby I., Lefranc F., Titeca G., Neuci S., Fastrez M., Dedecken L., Schäfer B.W., Brotchi J., Heizmann C.W., Pochet R., Salmon I., Kiss R., and Decaestecker C. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours. Neuropathol. Appl. Neurobiol. 26 (2000) 76-90
196. Hancq S., Salmon I., Brotchi J., De Witte O., Gabius H.J., Heizmann C.W., Kiss R., and Decaestecker C. S100A5: a marker of recurrence in WHO grade I meningiomas. Neuropathol. Appl. Neurobiol. 30 (2004) 178-187
197. 2+-dependent affinity chromatography. Eur. J. Biochem. 195 (1991) 795-800
198. Kuznicki J., Filipek A., Hunziker P.E., Huber S., and Heizmann C.W. Calcium-binding protein from mouse Ehrlich ascites-tumour cells is homologous to human calcyclin. Biochem. J. 263 (1989) 951-956
199. Kuznicki J., Filipek A., Heimann P., Kaczmarek L., and Kaminska B. Tissue specific distribution of calcyclin-10.5 kDa Ca2+-binding protein. FEBS Lett. 254 (1989) 141-144
200. Stradal T.B., and Gimona M. Ca(2+)-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope. J. Biol. Chem. 274 (1999) 31593-31596
201. Hsieh H.L., Schafer B.W., Cox J.A., and Heizmann C.W. S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells. J. Cell. Sci. 115 (2002) 3149-3158
202. Filipek A., Jastrzebska B., Nowotny M., Kwiatkowska K., Hetman M., Surmacz L., Wyroba E., and Kuznicki J. Ca2+-dependent translocation of the calcyclin-binding protein in neurons and neuroblastoma NB-2a cells. J. Biol. Chem. 277 (2002) 21103-21109
203. Filipek A., Heizmann C.W., and Kuznicki J. Calcyclin is a calcium and zinc binding protein. FEBS Lett. 264 (1990) 263-266
204. Potts B.C., Smith J., Akke M., Macke T.J., Okazaki K., Hidaka H., Case D.A., and Chazin W.J. The structure of calcyclin reveals a novel homodimeric fold for S100 Ca(2+)-binding proteins. Nat. Struct. Biol. 2 (1995) 790-796
205. Sastry M., Ketchem R.R., Crescenzi O., Weber C., Lubienski M.J., Hidaka H., and Chazin W.J. The three-dimensional structure of Ca(2+)-bound calcyclin: implications for Ca(2+)-signal transduction by S100 proteins. Structure 6 (1998) 223-231
206. Otterbein L.R., Kordowska J., Witte-Hoffmann C., Wang C.L., and Dominguez R. Crystal structures of S100A6 in the Ca(2+)-free and Ca(2+)-bound states: the calcium sensor mechanism of S100 proteins revealed at atomic resolution. Structure 10 (2002) 557-567
207. Komatsu K., Andoh A., Ishiguro S., Suzuki N., Hunai H., Kobune-Fujiwara Y., Kameyama M., Miyoshi J., Akedo H., and Nakamura H. Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin. Cancer Res. 6 (2000) 172-177
208. De Petris L., Orre L.M., Kanter L., Pernemalm M., Koyi H., Lewensohn R., and Lehtio J. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer (2008) [Electronic publication ahead of print]
209. Ohuchida K., Mizumoto K., Yu J., Yamaguchi H., Konomi H., Nagai E., Yamaguchi K., Tsuneyoshi M., and Tanaka M. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol., Biomarkers Prev. 16 (2007) 649-654
210. Yang Y.Q., Zhang L.J., Dong H., Jiang C.L., Zhu Z.G., Wu J.X., Wu Y.L., Han J.S., Xiao H.S., Gao H.J., and Zhang Q.H. Upregulated expression of S100A6 in human gastric cancer. J. Dig. Dis. 8 (2007) 186-193
211. Vimalachandran D., Greenhalf W., Thompson C., Luttges J., Prime W., Campbell F., Dodson A., Watson R., Crnogorac-Jurcevic T., Lemoine N., Neoptolemos J., and Costello E. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 65 (2005) 3218-3225
212. Hoyaux D., Alao J., Fuchs J., Kiss R., Keller B., Heizmann C.W., Pochet R., and Frermann D. S100A6, a calcium- and zinc-binding protein, is overexpressed in SOD1 mutant mice, a model for amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1498 (2000) 264-272
213. Boom A., Pochet R., Authelet M., Pradier L., Borghgraef P., Van Leuven F., Heizmann C.W., and Brion J.P. Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models. Biochim. Biophys. Acta 1742 (2004) 161-168
214. Filipek A., Jastrzebska B., Nowotny M., and Kuznicki J. CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J. Biol. Chem. 277 (2002) 28848-28852
215. 2+-dependent binding of calcyclin to muscle tropomyosin. Biochem. Biophys. Res. Commun. 220 (1996) 360-365
216. Filipek A., Wojda U., and Lesniak W. Interaction of calcyclin and its cyanogen bromide fragments with annexin II and glyceraldehyde 3-phosphate dehydrogenase. Int. J. Biochem. Cell. Biol. 27 (1995) 1123-1131
217. Sudo T., and Hidaka H. Regulation of calcyclin (S100A6) binding by alternative splicing in the N-terminal regulatory domain of annexin XI isoforms. J. Biol. Chem. 273 (1998) 6351-6357
218. Watanabe M., Ando Y., Tokumitsu H., and Hidaka H. Binding site of annexin XI on the calcyclin molecule. Biochem. Biophys. Res. Commun. 196 (1993) 1376-1382
219. Zeng F.Y., Gerke V., and Gabius H.J. Identification of annexin II, annexin VI and glyceraldehyde-3-phosphate dehydrogenase as calcyclin-binding proteins in bovine heart. Int J. Biochem. 25 (1993) 1019-1027
220. Madsen P., Rasmussen H.H., Leffers H., Honore B., Dejgaard K., Olsen E., Kiil J., Walbum E., Andersen A.H., Basse B., et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 97 (1991) 701-712
221. Vorum H., Madsen P., Rasmussen H.H., Etzerodt M., Svendsen I., Celis J.E., and Honore B. Expression and divalent cation binding properties of the novel chemotactic inflammatory protein psoriasin. Electrophoresis 17 (1996) 1787-1796
222. Brodersen D.E., Etzerodt M., Madsen P., Celis J.E., Thogersen H.C., Nyborg J., and Kjeldgaard M. EF-hands at atomic resolution: the structure of human psoriasin (S100A7) solved by MAD phasing. Structure 6 (1998) 477-489
223. 2+-free states. Biochemistry 38 (1999) 1695-1704
224. Zhang H., Wang Y., Chen Y., Sun S., Li N., Lv D., Liu C., Huang L., He D., and Xiao X. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 57 (2007) 37-45
225. Krop I., Marz A., Carlsson H., Li X., Bloushtain-Qimron N., Hu M., Gelman R., Sabel M.S., Schnitt S., Ramaswamy S., Kleer C.G., Enerback C., and Polyak K. A putative role for psoriasin in breast tumor progression. Cancer Res 65 (2005) 11326-11334
226. Petersson S., Bylander A., Yhr M., and Enerback C. S100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells. BMC Cancer 7 (2007) 205-214
227. Hagens G., Roulin K., Hotz R., Saurat J.H., Hellman U., and Siegenthaler G. Probable interaction between S100A7 and E-FABP in the cytosol of human keratinocytes from psoriatic scales. Mol. Cell. Biochem. 192 (1999) 123-128
228. Ruse M., Broome A.M., and Eckert R.L. S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes. J. Invest. Dermatol. 121 (2003) 132-141
229. Emberley E.D., Gietz R.D., Campbell J.D., HayGlass K.T., Murphy L.C., and Watson P.H. RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer 2 (2002) 28-35
230. Emberley E.D., Niu Y., Leygue E., Tomes L., Gietz R.D., Murphy L.C., and Watson P.H. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res. 63 (2003) 1954-1961
231. Wolf R., Howard O.M., Dong H.F., Voscopoulos C., Boeshans K., Winston J., Divi R., Gunsior M., Goldsmith P., Ahvazi B., Chavakis T., Oppenheim J.J., and Yuspa S.H. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol. 181 (2008) 1499-1506
232. Lagasse E., and Clerc R.G. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation. Mol. Cell. Biol. 8 (1988) 2402-2410
233. Murao S., Collart F., and Huberman E. A protein complex expressed during terminal differentiation of monomyelocytic cells is an inhibitor of cell growth. Cell. Growth Differ. 1 (1990) 447-454
234. Yui S., Mikami M., and Yamazaki M. Purification and characterization of the cytotoxic factor in rat peritoneal exudate cells: its identification as the calcium binding protein complex, calprotectin. J. Leukocyte Biol. 58 (1995) 307-316
235. Brandtzaeg P., Gabrielsen T.O., Dale I., Muller F., Steinbakk M., and Fagerhol M.K. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv. Exp. Med. Biol. 371A (1995) 201-206
236. Rugtveit J., Scott H., Halstensen T.S., Fausa O., and Brandtzaeg P. Differential expression of leucocyte protein L1 (calprotectin) by monocytes and intestinal macrophages. Adv. Exp. Med. Biol. 371A (1995) 207-210
237. Kelly S.E., Jones D.B., and Fleming S. Calgranulin expression in inflammatory dermatoses. J. Pathol. 159 (1989) 17-21
238. Vogl T., Roth J., Sorg C., Hillenkamp F., and Strupat K. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 10 (1999) 1124-1130
239. Vogl T., Leukert N., Barczyk K., Strupat K., and Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim. Biophys. Acta 1763 (2006) 1298-1306
240. Korndorfer I.P., Brueckner F., and Skerra A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J. Mol. Biol. 370 (2007) 887-898
241. Ishikawa K., Nakagawa A., Tanaka I., Suzuki M., and Nishihira J. The structure of human MRP8, a member of the S100 calcium-binding protein family, by MAD phasing at 1.9 A resolution. Acta Crystallogr., D Biol. Crystallogr. 56 Pt. 5 (2000) 559-566
242. Itou H., Yao M., Fujita I., Watanabe N., Suzuki M., Nishihira J., and Tanaka I. The crystal structure of human MRP14 (S100A9), a Ca(2+)-dependent regulator protein in inflammatory process. J. Mol. Biol. 316 (2002) 265-276
243. Zwadlo G., Bruggen J., Gerhards G., Schlegel R., and Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin. Exp. Immunol. 72 (1988) 510-515
244. Sohnle P.G., Hunter M.J., Hahn B., and Chazin W.J. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J. Infect. Dis. 182 (2000) 1272-1275
245. 2+-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 56 (1995) 406-414
246. Ehlermann P., Eggers K., Bierhaus A., Most P., Weichenhan D., Greten J., Nawroth P.P., Katus H.A., and Remppis A. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc. Diabetol. 5 (2006) 6-15
247. Foell D., Wittkowski H., Ren Z., Turton J., Pang G., Daebritz J., Ehrchen J., Heidemann J., Borody T., Roth J., and Clancy R. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 216 (2008) 183-192
248. Postler E., Lehr A., Schluesener H., and Meyermann R. Expression of the S-100 proteins MRP-8 and -14 in ischemic brain lesions. Glia 19 (1997) 27-34
249. Akiyama H., Ikeda K., Katoh M., McGeer E.G., and McGeer P.L. Expression of MRP14, 27E10, interferon-alpha and leukocyte common antigen by reactive microglia in postmortem human brain tissue. J. Neuroimmunol. 50 (1994) 195-201
250. Kerkhoff C., Klempt M., and Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim. Biophys. Acta 1448 (1998) 200-211
251. Yong H.Y., and Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch. Pharm. Res. 30 (2007) 75-81
252. Hermani A., De Servi B., Medunjanin S., Tessier P.A., and Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp. Cell Res. 312 (2006) 184-197
253. Stulik J., Osterreicher J., Koupilova K., Knizek, Macela A., Bures J., Jandik P., Langr F., Dedic K., and Jungblut P.R. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 20 (1999) 1047-1054
254. Hermani A., Hess J., De Servi B., Medunjanin S., Grobholz R., Trojan L., Angel P., and Mayer D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 11 (2005) 5146-5152
255. Passey R.J., Williams E., Lichanska A.M., Wells C., Hu S., Geczy C.L., Little M.H., and Hume D.A. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J. Immunol. 163 (1999) 2209-2216
256. Manitz M.P., Horst B., Seeliger S., Strey A., Skryabin B.V., Gunzer M., Frings W., Schonlau F., Roth J., Sorg C., and Nacken W. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23 (2003) 1034-1043
257. Hobbs J.A., May R., Tanousis K., McNeill E., Mathies M., Gebhardt C., Henderson R., Robinson M.J., and Hogg N. Myeloid cell function in MRP-14 (S100A9) null mice. Mol. Cell. Biol. 23 (2003) 2564-2576
258. Kerkhoff C., Sorg C., Tandon N.N., and Nacken W. Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry 40 (2001) 241-248
259. Robinson M.J., Tessier P., Poulsom R., and Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J. Biol. Chem. 277 (2002) 3658-3665
260. Kerkhoff C., Nacken W., Benedyk M., Dagher M.C., Sopalla C., and Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 19 (2005) 467-469
261. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., Nacken W., Foell D., van der Poll T., Sorg C., and Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13 (2007) 1042-1049
262. Boyd J.H., Kan B., Roberts H., Wang Y., and Walley K.R. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ. Res. 102 (2008) 1239-1246
263. Ghavami S., Rashedi I., Dattilo B.M., Eshraghi M., Chazin W.J., Hashemi M., Wesselborg S., Kerkhoff C., and Los M. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukocyte Biol. 83 (2008) 1484-1492
264. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Yamamoto H., Chazin W.J., Nakatani Y., Yui S., and Makino H. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis. Res. Ther. 8 (2006) R69
265. Ghavami S., Kerkhoff C., Chazin W.J., Kadkhoda K., Xiao W., Zuse A., Hashemi M., Eshraghi M., Schulze-Osthoff K., Klonisch T., and Los M. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim. Biophys. Acta 1783 (2008) 297-311
266. Andrassy M., Igwe J., Autschbach F., Volz C., Remppis A., Neurath M.F., Schleicher E., Humpert P.M., Wendt T., Liliensiek B., Morcos M., Schiekofer S., Thiele K., Chen J., Kientsch-Engel R., Schmidt A.M., Stremmel W., Stern D.M., Katus H.A., Nawroth P.P., and Bierhaus A. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am. J. Pathol. 169 (2006) 1223-1237
267. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P.P., Bierhaus A., Varki N., Kronenberg M., Freeze H.H., and Srikrishna G. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29 (2008) 2035-2043
268. 2+-binding properties of calgizzarin (S100C) isolated from chicken gizzard smooth muscle. Biochem. Cell. Biol. 74 (1996) 687-694
269. Schonekess B.O., and Walsh M.P. Molecular cloning and expression of avian smooth muscle S100A11 (calgizzarin, S100C). Biochem. Cell. Biol. 75 (1997) 771-775
270. Dempsey A.C., Walsh M.P., and Shaw G.S. Unmasking the annexin I interaction from the structure of Apo-S100A11. Structure 11 (2003) 887-897
271. Rety S., Osterloh D., Arie J.P., Tabaries S., Seeman J., Russo-Marie F., Gerke V., and Lewit-Bentley A. Structural basis of the Ca(2+)-dependent association between S100C (S100A11) and its target, the N-terminal part of annexin I. Struct. Fold Des. 8 (2000) 175-184
272. Murzik U., Hemmerich P., Weidtkamp-Peters S., Ulbricht T., Bussen W., Hentschel J., von Eggeling F., and Melle C. Rad54B targeting to DNA double-strand break repair sites requires complex formation with S100A11. Mol. Biol. Cell 19 (2008) 2926-2935
273. Rehman I., Azzouzi A.R., Cross S.S., Deloulme J.C., Catto J.W., Wylde N., Larre S., Champigneuille J., and Hamdy F.C. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum. Pathol. 35 (2004) 1385-1391
274. Cross S.S., Hamdy F.C., Deloulme J.C., and Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46 (2005) 256-259
275. Ohuchida K., Mizumoto K., Ohhashi S., Yamaguchi H., Konomi H., Nagai E., Yamaguchi K., Tsuneyoshi M., and Tanaka M. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin. Cancer Res. 12 (2006) 5417-5422
276. Memon A.A., Sorensen B.S., Meldgaard P., Fokdal L., Thykjaer T., and Nexo E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin. Cancer Res. 11 (2005) 606-611
277. Kondo A., Sakaguchi M., Makino E., Namba M., Okada S., and Huh N.H. Localization of S100C immunoreactivity in various human tissues. Acta Med. Okayama 56 (2002) 31-34
278. 2+- and TGFbeta-induced inhibition of growth of normal human keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13921-13926
279. Sakaguchi M., Miyazaki M., Sonegawa H., Kashiwagi M., Ohba M., Kuroki T., Namba M., and Huh N.H. PKCalpha mediates TGFbeta-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11. J. Cell Biol. 164 (2004) 979-984
280. Mannan A.U., Nica G., Nayernia K., Mueller C., and Engel W. Calgizarrin like gene (Cal) deficient mice undergo normal spermatogenesis. Mol. Reprod. Dev. 66 (2003) 431-438
281. Cecil D.L., Johnson K., Rediske J., Lotz M., Schmidt A.M., and Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J. Immunol. 175 (2005) 8296-8302
282. Cecil D.L., and Terkeltaub R. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J. Immunol. 180 (2008) 8378-8385
283. Sakaguchi M., Sonegawa H., Murata H., Kitazoe M., Futami J., Kataoka K., Yamada H., and Huh N.H. S100A11, an Dual Mediator for Growth Regulation of Human Keratinocytes. Mol. Biol. Cell 19 (2008) 78-85
284. Guignard F., Mauel J., and Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem. J. 309 (1995) 395-401
285. Ilg E.C., Troxler H., Burgisser D.M., Kuster T., Markert M., Guignard F., Hunziker P., Birchler N., and Heizmann C.W. Amino acid sequence determination of human S100A12 (P6, calgranulin C, CGRP, CAAF1) by tandem mass spectrometry. Biochem. Biophys. Res. Commun. 225 (1996) 146-150
286. Yamashita K., Oyama Y., Shishibori T., Matsushita O., Okabe A., and Kobayashi R. Purification of bovine S100A12 from recombinant Escherichia coli. Protein Expression Purif. 16 (1999) 47-52
287. Garcia A.F., Garcia W., Nonato M.C., and Araujo A.P. Structural stability and reversible unfolding of recombinant porcine S100A12. Biophys. Chem. 134 (2008) 246-253
288. Dell'Angelica E.C., Schleicher C.H., and Santome J.A. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269 (1994) 28929-28936
289. Moroz O.V., Antson A.A., Murshudov G.N., Maitland N.J., Dodson G.G., Wilson K.S., Skibshoj I., Lukanidin E.M., and Bronstein I.B. The three-dimensional structure of human S100A12. Acta Crystallogr., D Biol. Crystallogr. 57 (2001) 20-29
290. Moroz O.V., Antson A.A., Grist S.J., Maitland N.J., Dodson G.G., Wilson K.S., Lukanidin E., and Bronstein I.B. Structure of the human S100A12-copper complex: implications for host-parasite defence. Acta Crystallogr., D Biol. Crystallogr. 59 (2003) 859-867
291. Foell D., Ichida F., Vogl T., Yu X., Chen R., Miyawaki T., Sorg C., and Roth J. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361 (2003) 1270-1272
292. Foell D., Kane D., Bresnihan B., Vogl T., Nacken W., Sorg C., Fitzgerald O., and Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 42 (2003) 1383-1389
293. Foell D., Kucharzik T., Kraft M., Vogl T., Sorg C., Domschke W., and Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52 (2003) 847-853
294. Foell D., Seeliger S., Vogl T., Koch H.G., Maschek H., Harms E., Sorg C., and Roth J. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58 (2003) 613-617
295. Mori Y., Kosaki A., Kishimoto N., Kimura T., Iida K., Fukui M., Nakajima F., Nagahara M., Urakami M., Iwasaka T., and Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am. J. Nephrol. 29 (2008) 18-24
296. Sidler M.A., Leach S.T., and Day A.S. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm. Bowel. Dis. 14 (2008) 359-366
297. Pietzsch J., and Hoppmann S. Human S100A12: a novel key player in inflammation?. Amino Acids (2008) [Electronic publication ahead of print]
298. Lutzow Y.C., Donaldson L., Gray C.P., Vuocolo T., Pearson R.D., Reverter A., Byrne K.A., Sheehy P.A., Windon R., and Tellam R.L. Identification of immune genes and proteins involved in the response of bovine mammary tissue to Staphylococcus aureus infection. BMC Vet. Res. 4 (2008) 18-42
299. Leach S.T., Mitchell H.M., Geczy C.L., Sherman P.M., and Day A.S. S100 calgranulin proteins S100A8, S100A9 and S100A12 are expressed in the inflamed gastric mucosa of Helicobacter pylori-infected children. Can. J. Gastroenterol. 22 (2008) 461-464
300. Mikkelsen S.E., Novitskaya V., Kriajevska M., Berezin V., Bock E., Norrild B., and Lukanidin E. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J. Neurochem. 79 (2001) 767-776
301. Hatakeyama T., Okada M., Shimamoto S., Kubota Y., and Kobayashi R. Identification of intracellular target proteins of the calcium-signaling protein S100A12. Eur. J. Biochem. 271 (2004) 3765-3775
302. Wicki R., Schäfer B.W., Erne P., and Heizmann C.W. Characterization of the human and mouse cDNAs coding for S100A13, a new member of the S100 protein family. Biochem. Biophys. Res. Commun. 227 (1996) 594-599
303. Ridinger K., Schäfer B.W., Durussel I., Cox J.A., and Heizmann C.W. S100A13. Biochemical characterization and subcellular localization in different cell lines. J. Biol. Chem. 275 (2000) 8686-8694
304. Sivaraja V., Kumar T.K., Rajalingam D., Graziani I., Prudovsky I., and Yu C. Copper binding affinity of S100A13, a key component of the FGF-1 nonclassical copper-dependent release complex. Biophys. J. 91 (2006) 1832-1843
305. Landriscina M., Schinzari G., Di Leonardo G., Quirino M., Cassano A., D'Argento E., Lauriola L., Scerrati M., Prudovsky I., and Barone C. S100A13, a new marker of angiogenesis in human astrocytic gliomas. J. Neuro-Oncol. 80 (2006) 251-259
306. Pierce A., Barron N., Linehan R., Ryan E., O'Driscoll L., Daly C., and Clynes M. Indentification of a novel, functionnal role for S100A13 in invasive lung cancer cell lines. Eur. J. Cancer 44 (2008) 151-159
307. Landriscina M., Soldi R., Bagala C., Micucci I., Bellum S., Tarantini F., Prudovsky I., and Maciag T. S100A13 participates in the release of fibroblast growth factor 1 in response to heat shock in vitro. J. Biol. Chem. 276 (2001) 22544-22552
308. 2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1. Neurochem. Int. 52 (2008) 1076-1085
309. Hsieh H.L., Schäfer B.W., Weigle B., and Heizmann C.W. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem. Biophys. Res. Commun. 316 (2004) 949-959
310. 2+ binding properties. Eur. J. Biochem. 207 (1992) 541-547
311. 2+-binding protein. Mol. Biol. Rep. 30 (2003) 243-248
312. Parkkila S., Pan P.W., Ward A., Gibadulinova A., Oveckova I., Pastorekova S., Pastorek J., Martinez A.R., Helin H.O., and Isola J. The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin. Pathol. 8 (2008) 2-11
313. Ishii Y., Kasukabe T., and Honma Y. Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim. Biophys. Acta 1745 (2005) 156-165
314. Arumugam T., Simeone D.M., Van Golen K., and Logsdon C.D. S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 11 (2005) 5356-5364
315. Guerreiro Da Silva I.D., Hu Y.F., Russo I.H., Ao X., Salicioni A.M., Yang X., and Russo J. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int. J. Oncol. 16 (2000) 231-240
316. Mackay A., Jones C., Dexter T., Silva R.L., Bulmer K., Jones A., Simpson P., Harris R.A., Jat P.S., Neville A.M., Reis L.F., Lakhani S.R., and O'Hare M.J. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22 (2003) 2680-2688
317. Koltzscher M., Neumann C., Konig S., and Gerke V. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol. Biol. Cell 14 (2003) 2372-2384
318. Austermann J., Nazmi A.R., Muller-Tidow C., and Gerke V. Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J. Biol. Chem. 283 (2008) 29331-29340
319. Dowen S.E., Crnogorac-Jurcevic T., Gangeswaran R., Hansen M., Eloranta J.J., Bhakta V., Brentnall T.A., Luttges J., Kloppel G., and Lemoine N.R. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 166 (2005) 81-92
320. Arumugam T., Simeone D.M., Schmidt A.M., and Logsdon C.D. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem. 279 (2004) 5059-5065
321. Fuentes M.K., Nigavekar S.S., Arumugam T., Logsdon C.D., Schmidt A.M., Park J.C., and Huang E.H. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon. Rectum. 50 (2007) 1230-1240
322. Lin L.H., Van Eldik L.J., Osheroff N., and Norden J.J. Inhibition of protein kinase C- and casein kinase II-mediated phosphorylation of GAP-43 by S100 beta. Brain Res. Mol. Brain Res. 25 (1994) 297-304
323. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 263 (1988) 5876-5883
324. Ziegler D.R., Innocente C.E., Leal R.B., Rodnight R., and Goncalves C.A. The S100B protein inhibits phosphorylation of GFAP and vimentin in a cytoskeletal fraction from immature rat hippocampus. Neurochem. Res. 23 (1998) 1259-1263
325. Frizzo J.K., Tramontina F., Bortoli E., Gottfried C., Leal R.B., Lengyel I., Donato R., Dunkley P.R., and Goncalves C.A. S100B-mediated inhibition of the phosphorylation of GFAP is prevented by TRTK-12. Neurochem. Res. 29 (2004) 735-740
326. Sorci G., Agneletti A.L., Bianchi R., and Donato R. Association of S100B with intermediate filaments and microtubules in glial cells. Biochim. Biophys. Acta 1448 (1998) 277-289
327. Garbuglia M., Verzini M., and Donato R. Annexin VI binds S100A1 and S100B and blocks the ability of S100A1 and S100B to inhibit desmin and GFAP assemblies into intermediate filaments. Cell Calcium 24 (1998) 177-191
328. Garbuglia M., Verzini M., Hofmann A., Huber R., and Donato R. S100A1 and S100B interactions with annexins. Biochim. Biophys. Acta 1498 (2000) 192-206
329. Arcuri C., Giambanco I., Bianchi R., and Donato R. Annexin V, annexin VI, S100A1 and S100B in developing and adult avian skeletal muscles. Neuroscience 109 (2002) 371-388
330. Delphin C., Ronjat M., Deloulme J.C., Garin G., Debussche L., Higashimoto Y., Sakaguchi K., and Baudier J. Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53. J. Biol. Chem. 274 (1999) 10539-10544
331. Fernandez-Fernandez M.R., Veprintsev D.B., and Fersht A.R. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4735-4740
332. Nowotny M., Spiechowicz M., Jastrzebska B., Filipek A., Kitagawa K., and Kuznicki J. Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins. J. Biol. Chem. 278 (2003) 26923-26928
333. Gentil B.J., Delphin C., Mbele G.O., Deloulme J.C., Ferro M., Garin J., and Baudier J. The giant protein AHNAK is a specific target for the calcium- and zinc-binding S100B protein: potential implications for Ca2+ homeostasis regulation by S100B. J. Biol. Chem. 276 (2001) 23253-23261
334. Landar A., Caddell G., Chessher J., and Zimmer D.B. Identification of an S100A1/S100B target protein: phosphoglucomutase. Cell Calcium 20 (1996) 279-285
335. Zimmer D.B., and Van Eldik L.J. Identification of a molecular target for the calcium-modulated protein S100. Fructose-1,6-bisphosphate aldolase. J. Biol. Chem. 261 (1986) 11424-11428
336. Fujii T., Oomatsuzawa A., Kuzumaki N., and Kondo Y. Calcium-dependent regulation of smooth muscle calponin by S100. J. Biochem. 116 (1994) 121-127
337. Skripnikova E.V., and Gusev N.B. Interaction of smooth muscle caldesmon with S-100 protein. FEBS Lett. 257 (1989) 380-382
338. Okazaki K., Obata N.H., Inoue S., and Hidaka H. S100 beta is a target protein of neurocalcin delta, an abundant isoform in glial cells. Biochem. J. 306 (1995) 551-555
339. Ivanenkov V.V., Jamieson Jr. G.A., Gruenstein E., and Dimlich R.V. Characterization of S-100b binding epitopes. Identification of a novel target, the actin capping protein, CapZ. J. Biol. Chem. 270 (1995) 14651-14658
340. Zimmer D.B., and Dubuisson J.G. Identification of an S100 target protein: glycogen phosphorylase. Cell Calcium 14 (1993) 323-332
341. 2+-activated) adenylate cyclase activity associated with skeletal muscle membranes. FEBS Lett. 248 (1989) 9-12
342. Donato R. Calcium-independent, pH-regulated effects of S-100 proteins on assembly-disassembly of brain microtubule protein in vitro. J. Biol. Chem. 263 (1988) 106-110
343. Baudier J., Bergeret E., Bertacchi N., Weintraub H., Gagnon J., and Garin J. Interactions of myogenic bHLH transcription factors with calcium-binding calmodulin and S100a (alpha alpha) proteins. Biochemistry 34 (1995) 7834-7846
344. Garbuglia M., Verzini M., Rustandi R.R., Osterloh D., Weber D.J., Gerke V., and Donato R. Role of the C-terminal extension in the interaction of S100A1 with GFAP, tubulin, the S100A1- and S100B-inhibitory peptide, TRTK-12, and a peptide derived from p53, and the S100A1 inhibitory effect on GFAP polymerization. Biochem. Biophys. Res. Commun. 254 (1999) 36-41
345. 2+/S100A1-interacting proteins. Biochem. J. 344 (1999) 577-583
346. Benfenati F., Ferrari R., Onofri F., Arcuri C., Giambanco I., and Donato R. S100A1 codistributes with synapsin I in discrete brain areas and inhibits the F-actin-bundling activity of synapsin I. J. Neurochem. 89 (2004) 1260-1270
347. Treves S., Scutari E., Robert M., Groh S., Ottolia M., Prestipino G., Ronjat M., and Zorzato F. Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry 36 (1997) 11496-11503
348. 2+-binding proteins. Eur. J. Biochem. 249 (1997) 127-133
349. 2+ -ATPase2a and phospholamban in the human heart. Biochem. Biophys. Res. Commun. 306 (2003) 550-557
350. 2+-cycling in ventricular rat cardiomyocytes. J. Cell. Sci. 118 (2005) 421-431
351. Okada M., Hatakeyama T., Itoh H., Tokuta N., Tokumitsu H., and Kobayashi R. S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex. J. Biol. Chem. 279 (2004) 4221-4233
352. Yamasaki R., Berri M., Wu Y., Trombitas K., McNabb M., Kellermayer M.S., Witt C., Labeit D., Labeit S., Greaser M., and Granzier H. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys. J. 81 (2001) 2297-2313
353. Parker C., Lakshmi M.S., Piura B., and Sherbet G.V. Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma. DNA Cell. Biol. 13 (1994) 343-351
354. Ford H.L., and Zain S.B. Interaction of metastasis associated Mts1 protein with nonmuscle myosin. Oncogene 10 (1995) 1597-1605
355. 2+-dependent binding to 36-kDa microfibril-associated glycoprotein. J. Biol. Chem. 267 (1992) 17136-17140
356. Filipek A., and Wojda U. p30, a novel protein target of mouse calcyclin (S100A6). Biochem. J. 320 (1996) 585-587
357. Rintala-Dempsey A.C., Santamaria-Kisiel L., Liao Y., Lajoie G., and Shaw G.S. Insights into S100 target specificity examined by a new interaction between S100A11 and annexin A2. Biochemistry 45 (2006) 14695-14705